Alzheimer's disease (AD) is a major global public health threat for which we have very limited responses. Solutions will come only though research. The AD Centers (ADC) Program is a leading effort by the US under the responsibility of the National Institute on Aging (NIA) to develop solutions for AD. The central research strategy of NIA is Seeking the Earliest Interventions. The University of Washington (UW) ADC is one of fifteen AD Research Centers (ADRCs), and we contribute uniquely to this premier program through our vision of precision medicine for AD: comprehensive classification of an individual's risk; surveillance with accurate and early detection of patho-physiologic processes while still preclinical; and interventions tailored to an individual's molecular drivers of disease All components of UW ADRC are focused on this vision and our 5-year mission of creating the knowledge and tools needed to advance preclinical biomarkers and develop experimental therapeutics, while also enthusiastically participating in (inter)national collaborations in clinicl trials, AD genetics, brain aging, diagnostics, and outreach to disparities populations. UW ADRC balances stability with innovation. Stability in the leadership of our required Cores assures highest quality outcomes for the ADC Program. Innovation draws on the vast resources of UW to develop three new Projects, a new Satellite Core, and a new component of our Clinical Core to fuel discoveries. UW ADRC resonates strongly with the three principles of National Plan to Address Alzheimer's Disease, especially its third: transform the way we approach AD. Successful completion of our 5-year mission will hasten this transformation to the right intervention for the right person at the right time - precision medicine for AD.

Public Health Relevance

Alzheimer's disease (AD) is the 4th leading cause of death in the US and by far the fastest-increasing cause of US deaths. Currently, there are limited responses to this major public health threat; solutions will come only from research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005136-33
Application #
9088230
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
1997-05-01
Project End
2020-04-30
Budget Start
2016-08-01
Budget End
2017-04-30
Support Year
33
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Washington
Department
Psychiatry
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Nafikov, Rafael A; Nato Jr, Alejandro Q; Sohi, Harkirat et al. (2018) Analysis of pedigree data in populations with multiple ancestries: Strategies for dealing with admixture in Caribbean Hispanic families from the ADSP. Genet Epidemiol 42:500-515
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Young, Jessica E; Fong, Lauren K; Frankowski, Harald et al. (2018) Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem Cell Reports 10:1046-1058
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064
Wang, Lucy Y; Raskind, Murray A; Wilkinson, Charles W et al. (2018) Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia. Int J Geriatr Psychiatry 33:763-768
Moreno, Monica A; Or-Geva, Noga; Aftab, Blake T et al. (2018) Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurol Neuroimmunol Neuroinflamm 5:e466

Showing the most recent 10 out of 753 publications